Canton Strategic Holdings (CNTN) Gains from Investment Securities (2020 - 2026)
Canton Strategic Holdings posted quarterly Gains from Investment Securities of $656163.0 for Q1 2026, up 170.26% year-on-year from $242788.0 in Q1 2025, and little changed on a QoQ basis from $657042.0 in Q4 2025.
Canton Strategic Holdings (CNTN) has 7 years of Gains from Investment Securities data on file, last reported at $656163.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 170.26% year-over-year to $656163.0; the trailing twelve-month figure through Mar 2026 stood at $656163.0 (up 170.26% YoY), and the FY2025 full-year result was $657042.0, up 503.04% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $656163.0, roughly flat from $657042.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $657042.0 in Q4 2025 and bottomed at $582.0 in Q2 2025.
- The 5-year median for Gains from Investment Securities is $61579.5 (2022), against an average of $230359.9.
- Peak annual rise in Gains from Investment Securities reached 13042.28% in 2025, while the deepest fall reached 90.46% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $14204.0 in 2022, then tumbled by 57.04% to $6102.0 in 2023, then surged by 1685.56% to $108955.0 in 2024, then soared by 503.04% to $657042.0 in 2025, then retreated by 0.13% to $656163.0 in 2026.
- The last three Gains from Investment Securities figures came in at $656163.0 (Q1 2026), $657042.0 (Q4 2025), and $607042.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 656,163.00 |
| Mar 31, 2026 | 656,163.00 |
| Dec 31, 2025 | 657,042.00 |
| Dec 31, 2025 | 657,042.00 |
| Sep 30, 2025 | 607,042.00 |
| Sep 30, 2025 | 607,042.00 |
| Jun 30, 2025 | 582.00 |
| Jun 30, 2025 | 582.00 |
| Mar 31, 2025 | 242,788.00 |
| Mar 31, 2025 | 242,788.00 |
| Dec 31, 2024 | 108,955.00 |
| Dec 31, 2024 | 108,955.00 |
| Sep 30, 2024 | 4,619.00 |
| Sep 30, 2024 | 4,619.00 |
| Jun 30, 2024 | 6,102.00 |
| Jun 30, 2024 | 6,102.00 |
| Dec 31, 2023 | 6,102.00 |
| Dec 31, 2023 | 6,102.00 |
| Mar 31, 2022 | 14,204.00 |
| Mar 31, 2022 | 14,204.00 |
| Dec 31, 2021 | 903,468.00 |
| Dec 31, 2021 | 903,468.00 |
| Dec 31, 2020 | 675,731.00 |
| Dec 31, 2020 | 675,731.00 |